#covid vaccine registration in india

[colinwilson11]

The Rise Of CGAS-STING Pathway Market Therapies Will Lead To A Revolution In Cancer Immunotherapy

The CGAS-STING pathway market will grow at the highest pace owing to increasing R&D and growing potential of nucleic-acid sensing pathway modulators in cancer immunotherapy. The innate immune system recognizes nucleic acid species unique to pathogens via cytosolic DNA sensors and mediates type I interferon (IFN) responses that are critical for anti-viral immunity. Of these sensors, the cGAS-STING pathway couples cytosolic DNA sensing to type I IFN induction and downstream transcriptional programs. Once activated, cGAS produces the second messenger cyclic GMP-AMP (cGAMP) which binds and activates stimulator of IFN genes (STING). This signals the activation of downstream IFN regulatory factor 3 (IRF3) and NF-κB, leading to production of type I IFNs and pro-inflammatory cytokines.

The CGAS STING Pathway Market is estimated to be valued at US$ 0.46 Bn in 2024 and is expected to exhibit a CAGR of 25.% over the forecast period 2024-2031.

Growing significance of immunotherapy in cancer treatment and the advantages of targeting the cGAS-STING pathway such as involvement in sensing tumor DNA in the cytoplasm and activation of potent antitumor immunity has augmented the demand of associated drugs and therapies. The success of immunotherapy approaches has led to substantial investment in nucleic acid-sensing pathway modulators by pharmaceutical companies.

Key Takeaways

Key players operating in the cGAS-STING pathway are IFM Therapeutics, Bristol-Myers Squibb, Novartis, AstraZeneca, Merck & Co. Companies are investing heavily in R&D to develop novel therapeutics targeting this pathway. For instance, IFM Therapeutics is developing first-in-class STING agonist focusing on liver and gastrointestinal cancers in phase I/II clinical trial.

The demand for cGAS-STING therapies is increasing rapidly mainly due to growing demand for innovative cancer immunotherapies. According to American Cancer Society, around 1.9 million new cancer cases are diagnosed in the US annually presenting massive market potential. Additionally, improving accessibility of immunotherapy in developing countries will further drive the demand.

Advancements in understanding molecular mechanisms of cGAS-STING pathway activation and development of novel agonist and modulators have expanded therapeutic applications. Ongoing research for developing vaccines and combination therapies with checkpoint inhibitors holds promise to revolutionize cancer treatment through innate immunity activation.

Market Trends

Combination therapies research: There is growing focus on exploring synergies of cGAS-STING agonists with other immunotherapies like checkpoint inhibitors. Ongoing clinical trials evaluating combinations are demonstrating encouraging response rates.

Personalized medicine approach: Efforts are being made to develop biomarkers to predict response and identify patients likely to benefit from cGAS-STING therapies. This personalized approach can improve clinical outcomes.

Geographical expansion: Major players are expanding manufacturing and clinical trials to countries like China and India having huge patient pools. This will boost accessibility and commercialization prospects.

Market Opportunities

First STING agonist approval: IFM Therapeutics' lead molecule will be the first STING agonist examined in registrational trials paving way for first approval in 2026-27.

 Increased adoptability: As clinical evidence demonstrating benefits of cGAS-STING modulation emerges, adoption rate in treatment guidelines and clinical practice is expected to surge exponentially.

New therapeutic areas: Preliminary evidence shows cGAS-STING pathway also plays a role in autoimmune diseases providing scope for therapies in indications beyond oncology.

Impact Of COVID-19 On CGAS STING Pathway Market Growth

The COVID-19 pandemic has profoundly impacted the CGAS STING Pathway Market. During the initial outbreak in early 2020, the market recorded a decline as research activities slowed down and clinical trials faced interruptions due to lockdowns and social distancing norms. However, with shifting focus on immune therapies for tackling novel coronavirus infections, the interest in CGAS STING pathway modulators witnessed rapid growth. Many companies expedited their programs related to IFN activation via cGAS-STING pathway to develop host-directed antiviral therapies against SARS-CoV-2. The pandemic highlighted the need for developing strategies to strengthen innate immune responses via cGAS-STING pathway modulation. While clinical studies faced delays in 2020, collaborations between industry and research institutes intensified to advance immunotherapies targeting this pathway. Moving forward, the high growth projected for this market is expected to accelerate further on the back of strong ongoing research to evaluate potential of cGAS-STING pathway modulators as adjuvant or monotherapy for COVID-19.

Regional Concentration Of CGAS STING Pathway Market

North America currently dominates the CGAS STING Pathway Market and holds over 40% of the global market share in terms of value. This is due to high immunotherapies R&D spending and strong presence of key market players in the US. Moreover, the region is an early adopter of novel immune mechanisms and immune-oncology approaches. Within North America, the United States represents the most lucrative market owing to significant research funding and growing clinical adoption of STING agonists. On the other hand, Asia Pacific region is projected to witness the fastest growth during the forecast period with a CAGR of over 30%. This impressive growth can be attributed to rising healthcare expenditure, expanding clinical research infrastructure and growing focus of global pharma companies on emerging Asian markets. China and India are expected to spearhead the growth of CGAS STING Pathway Market in Asia Pacific region.

Europe currently represents the second largest regional market for CGAS STING pathway modulators globally. Availability of latest healthcare technologies, sophisticated research infrastructure and presence of major industry players have aided the growth of CGAS STING Pathway Market in Europe. Within the region, Germany, United Kingdom and France together hold around half of the total European market in terms of value. However, Eastern Europe is estimated to depict the fastest gains owing to increasing government spending to strengthen native research capabilities. Moreover, growing collaborations between European and US pharmaceutical firms will further stimulate market growth during the forecast period.

Get more insights on this topic:  https://www.trendingwebwire.com/cgas-sting-pathway-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-precision-cancer-immunotherapies/

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This CGAS STING Pathway Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the CGAS STING Pathway Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the CGAS STING Pathway Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- CGAS STING Pathway Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of CGAS STING Pathway Market vendors

FAQ’s

Q.1 What are the main factors influencing the CGAS STING Pathway Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top CGAS STING Pathway Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the CGAS STING Pathway Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[nbmsports]

Africa may need its own central medicines agency, says Aspen Pharmacare CEO

When Africa needs medicines, all too often the continent must look abroad. African nations consume about 25% of vaccines produced globally, but import nearly 99% of their supply, according to the African Union Development Agency. For packaged medicines, only 36% of demand is produced locally, and just 3% is supplied by regional trade, according to the World Economic Forum. Of the roughly 600 manufacturers of packaged medicines operating on the continent, South Africa’s Aspen Pharmacare is one of the largest, with more than 9,000 employees in over 50 countries. CEO Stephen Saad discussed the future of the pharmaceutical sector in Africa, and what lessons Aspen Pharmacare has learned from the Covid-19 pandemic, with CNN’s Eleni Giokos. The following interview has been edited for length and clarity. During the pandemic, we’ve seen a spotlight on the inequalities that exist on the continent in the pharmaceutical sector. Aspen has had a very strong commercial presence across Africa and now you’re moving up the value chain. Certainly Covid has catalyzed a lot of work that you’re doing. Tell me what you’re up to. Saad: You mentioned inequalities. really sparked the world’s attention to say, ‘Hey, this doesn’t seem right.’ We were very proud to be able to deliver vaccines to the continent in the quantities that we did, but the reality of Covid was that Africa didn’t get vaccinated. But what we’ve learned — whether it was Aids or multi-drug-resistant TB — is that we have to be strong regionally. We have really doubled down and instead of saying, ‘Look we’ve lost the Covid vaccine volumes and so we’re closing up,’ we’ve actually put even more capacity. We’re committed to one person one vaccine in Africa and we’re working very hard towards that process. If I had to ask you to describe what the pharmaceutical sector looks like right now in Africa, what would your answer be? The answer is simple. When Covid came and Africa needed vaccines, over 90% of the vaccines were supplied by India — and that wasn’t great. At the end of the day, you can’t ask politicians from other countries to supply someone else before them. I don’t think anybody wants Africans to suffer, but the reality is when the borders close, whether it was Europe or India, they looked after their own population first. If it hadn’t been for Aspen, there would have been no vaccines made in Africa for the continent. There’s a lot of money going into it now, there’s a lot of investment, there are many initiatives — many of them government-driven. We, off our own bat, have decided that we want to be a source not just of vaccines but biologicals — we would really like to be assisting in oncology, diabetes. We’ve got a lot that we would like to do across the continent to make sure we get access, because there are so many diseases that are just so under-serviced. The World Trade Organization has done a lot on the policy front for Africa. The Continental Free Trade Area will hopefully make it a lot easier for cross-border trade in the pharmaceutical space. What challenges do you face? There are numerous challenges. We have facilities in Accra , Dar-es-Salaam , Nairobi … It is not always easy to get registrations approved. You decide not to put medicine in Kenya, for example, because of the cost of registration and the time taken. Whereas if it was already registered, we’d be exporting manufacturing into one of those territories. It’s not so much a tariff issue or a trade issue, this is really a regulatory issue, where your medicine is required to be registered in a specific country in a specific way. For example, you can register a product across Europe a central regulatory body. I think that is something that Africa should also consider. Even though you say you’re doing good, you still have to make money. How do you balance out all of these factors? There is this that for you to supply cost-affordably means that it’s not very profitable. So much is about economies of scale. I remember when we did ARVs and we were desperately trying to cut the price by nearly 90%. We got some fantastic pricing from everyone, but we still made a loss. The decision we made was, let’s go for it. At worst we would have a pretty expensive social investment project, but we backed ourselves that with increased volumes we would be able to reduce pricing. That’s what happened — the volumes came in, the prices, the technologies, and it became affordable. So sometimes you just have to go in and do it. I can’t tell you it was an exact science, but I do believe there’s a balance to be had. I do think the world acknowledges that there are people that can pay and there are people that can’t pay. To deny people that can’t pay simply because they don’t have money is not a model that’s sustainable. Source link Read the full article

[dlsphjournalism]

THE BMJ -- India investigates alleged leak of personal data from covid vaccination database

BY SHEFALI MALHOTRA (FGJ ‘23) -- The Indian government is investigating reports that the personal information of Indians stored on CoWIN, the Indian government’s web portal for covid-19 vaccination registration, might have been hacked. A reporter for Fourth News, a local newspaper in the southern state of Kerala in India, wrote on 11 June that a chatbot on Telegram, an instant messaging service, was sharing the personal information. READ MORE. 

[sabdiawaaz]

ਨਿੱਜੀ ਕੋਵਿਡ ਟੀਕਾਕਰਨ ਕੇਂਦਰ ਹੁਣ ਸਿਰਫ 150 ਰੁਪਏ ਤੱਕ ਹੀ ਵਸੂਲ ਸਕਦੇ ਨੇ

ਨਿੱਜੀ ਕੋਵਿਡ ਟੀਕਾਕਰਨ ਕੇਂਦਰ ਹੁਣ ਸਿਰਫ 150 ਰੁਪਏ ਤੱਕ ਹੀ ਵਸੂਲ ਸਕਦੇ ਨੇ

ਨਵੀਂ ਦਿੱਲੀ, 9 ਅਪ੍ਰੈਲ- 18 ਸਾਲ ਤੋਂ ਵੱਧ ਉਮਰ ਦੇ ਸਾਰਿਆਂ ਨੂੰ ਉਪਲਬਧ ਕਰਵਾਈ ਜਾ ਰਹੀ ‘ਸਾਵਧਾਨੀ ਖੁਰਾਕ’ ਤੋਂ ਇਕ ਦਿਨ ਪਹਿਲਾਂ ਕੇਂਦਰ ਨੇ ਸ਼ਨੀਵਾਰ ਨੂੰ ਕਿਹਾ ਕਿ ਨਿੱਜੀ ਕੋਵਿਡ-19 ਟੀਕਾਕਰਨ ਕੇਂਦਰ ਵੈਕ ਲਈ ਸੇਵਾ ਚਾਰਜ ਦੇ ਤੌਰ ‘ਤੇ ਵੱਧ ਤੋਂ ਵੱਧ 150 ਰੁਪਏ ਤੱਕ ਹੀ ਚਾਰਜ ਲੈ ਸਕਦੇ ਹਨ।

[spworldnews]

जर्मन नेताओं ने बिना टीकाकरण के नए COVID प्रतिबंधों को मंजूरी दी

जर्मन नेताओं ने बिना टीकाकरण के नए COVID प्रतिबंधों को मंजूरी दी

“एक टीका प्राप्त करें, एक बूस्टर प्राप्त करें – इस तरह हम इस संकट से बाहर निकलते हैं,” चांसलर-नामित ओलाफ स्कोल्ज़ ने कहा। निवर्तमान चांसलर एंजेला मर्केल ने कहा कि वह अनिवार्य टीकाकरण के पक्ष में हैं। जिन लोगों को अभी तक टीका नहीं लगाया गया है, उन्हें गुरुवार को जर्मन नेताओं की बातचीत के बाद अतिरिक्त प्रतिबंधों का सामना करना पड़ेगा। निवर्तमान जर्मन चांसलर एंजेला मर्केल और चांसलर-नामित ओलाफ…

[liferealthought]

Registration for Vaccine 18+ : क्या करना है। जानें पूरी प्रक्रिया और जरूरी बातें

Registration for Vaccine 18+ : क्या करना है। जानें पूरी प्रक्रिया और जरूरी बातें

देश इस वक्त कोरोना से जंग लड़ रहा ��ै। संकट की इस घड़ी में कोरोना वैक्सीनेशन ड्राइव को तेज किया गया है। 1 मई 2021 से देश में 18 वर्ष से ऊपर के लोगों को कोरोना वैक्सीन लगना शुरू हो जाएगा। इसके लिए 28 अप्रैल से रजिस्ट्रेशन शुरू होगा। स्वास्थ्य मंत्रालय ने ट्वीट कर जानकारी दी है कि वर्तमान में 45 वर्ष या उससे अधिक उम्र के लोग टीकाकरण किया जा रहा है। अगले महीने यानी  1 मई, 2021 से 18-45 वर्ष आयु वर्ग…

[avitaknews]

Covid-19 वैक्सीन लगवाने के लिए घर बैठे ऐसे करें Aarogya Setu ऐप पर खुद को रजिस्टर

Covid-19 वैक्सीन लगवाने के लिए घर बैठे ऐसे करें Aarogya Setu ऐप पर खुद को रजिस्टर

कोरोना वैक्सीनेशन के लिए अगर आप इधर-उधर जा रहे हैं तो रुक जाएं। क्योंकि हम आपको एक ऐसा तरीका बता रहे हैं जिसके जरिए आप घर बैठे इस वैक्सीन को लगवाने के लिए अपना या अपने परिवार में किसी का रजिस्ट्रेशन करा सकते हैं। इसके लिए आपको अपने फ़ोन में Aarogya Setu App डाउनलोड करना होगा और अगर आपके फ़ोन में ये ऐप है तो आसानी से इस ऐप के जरिए अपॉइंटमेंट ले सकते हैं। बता दें कि फिलहाल 60 साल से ज्‍यादा उम्र वाले…

[indizombie]

For decades now, India has been running one of the world's largest immunisation programmes that vaccinates tens of millions, including newborns and pregnant women, against various diseases. So experts believed India was well-prepared for the challenge. But the uptake has been slow because of vaccine scepticism as well as a lack of awareness among the poor or in rural areas. Many of the poor have little information on how to register themselves and access the vaccine free of cost. Online registration could be an impediment for those who don't own phones or use the internet. "There's very little public health communication for the poor and the working class regarding the vaccines," says Radha Khan, an independent consultant working in the field of gender, governance and social inclusion.

'India Covid-19 vaccination for 45+: Third phase launched as cases rise', BBC

[krazyshoppy]

केरल सरकार ने कोविड मानदंड उल्लंघनकर्ताओं को दंडित करके कमाए 350 करोड़ रुपये

केरल सरकार ने कोविड मानदंड उल्लंघनकर्ताओं को दंडित करके कमाए 350 करोड़ रुपये

देश और दुनिया में कोरोना वायरस के मामले लगातार बढ़ते जा रहे हैं. वहीं कोरोना के कारण कई लोगों की जान भी जा चुकी है. देश में कोरोना वायरस की रोकथाम के लिए कुछ राज्यों ने कई प्रतिबंध भी लगाए हुए थे. वहीं इन प्रतिबंधों के उल्लंघन पर जुर्माने का प्रावधान भी किया गया था. सरकारों ने जुर्माने भी काफी वसूले हैं. वहीं जुर्माने से केरल सरकार ने काफी भारी भरकम राशि वसूल की है. केरल सरकार ने दो साल पहले लगाए…

[blackmagicspecialist786-blog]

Omicron को भूलकर भी हल्के में लेने की न करें गलती, इन लोगों को जल्दी ले सकता है चपेट में

Omicron को भूलकर भी हल्के में लेने की न करें गलती, इन लोगों को जल्दी ले सकता है चपेट में

Omicron Cases in India: देश इस वक्त कोरोना वायरस की तीसरी लहर का सामना कर रहा है. कोरोना वायरस (Coronavirus) लोगों को अपने चपेट में ले रहा है, जिसके कारण कई लोगों की जान भी जा रही है. वहीं देश में कोरोना वायरस के नए वेरिएंट ओमिक्रोन का कहर भी देखने को मिल रहा है. लोग कोरोना वायरस के नए वेरिएंट ओमिक्रोन से भी संक्रमित हो रहे हैं. कई विशेषज्ञों का कहना है कि ओमिक्रोन वेरिएंट ज्यादा घातक नहीं है…

[sareideas]

भारत में 495 नए मामले सामने आए, कुल संख्या 2,630 तक पहुंची - Sareideas

भारत में 495 नए मामले सामने आए, कुल संख्या 2,630 तक पहुंची – Sareideas

डिजिटल डेस्क, नई दिल्ली। केंद्रीय स्वास्थ्य मंत्रालय ने कहा कि पिछले 24 घंटों में 495 ताजा मामले सामने आने के बाद भारत में ओमिक्रॉन मामलों की कुल संख्या बढ़कर 2,630 हो गई है, जिसमें महाराष्ट्र और दिल्ली सबसे ज्यादा प्रभावित हैं। मंत्रालय ने कहा, कुल मिलाकर, 995 लोग अब तक ठीक हो चुके हैं। 26 राज्यों और केंद्र शासित प्रदेशों में अब तक इस प्रकार का पता चला है। 797 ओमिक्रॉन मामलों के साथ महाराष्ट्र…

[doonitedin]

Coronavirus Omicron India Live Updates: GSK-Vir say their drug works against all Omicron mutations; Top US scientist says Omicron highly transmissible, but milder than previous variants

India’s active caseload currently stood at 95,014 on Tuesday — which was the lowest in 554 days.(Representational image/Reuters /File photo) Coronavirus Vaccine Registration, Coronavirus Omicron Variant Cases in India Live Updates: Four more international travellers were on Tuesday admitted to the Delhi government-run Lok Nayak Jai Prakash Narayan hospital’s special facility for isolating and…

[hummingzone]

Coronavirus Live News: India reports 15,823 new Covid-19 cases, 226 deaths in last 24 hours; US to reopen land borders for non-essential travel in November

The number of active cases in India has been falling sharply. Coronavirus Variants and Vaccinations, Coronavirus Active Cases in India Today News, October 13 Live Updates: In a major development in India’s fight against the Covid-19 pandemic, the Subject Expert Committee of India’s Central Drug Authority on Tuesday recommended granting emergency use approval to Bharat Biotech’s Covaxin for…

[atscorpsblog]

CoWin Portal पर खुद भी सुधार सकते हैं अपना वैक्सीनेशन सर्टिफिकेट, बेहद आसान है तरीका

CoWin Portal पर खुद भी सुधार सकते हैं अपना वैक्सीनेशन सर्टिफिकेट, बेहद आसान है तरीका

नई दिल्ली. देश में कोरोना वैक्सीनेशन सर्टिफिकेट (Vaccination Certificate) की उपयोगिता अब बढ़ती ही जा रही है. कई राज्यों और देशों ने वैक्सीनेशन सर्टिफिकेट के साथ यात्रा करना अनिवार्य (Mandatory to Travel) कर दिया है. हालांकि, देश में वैक्सीनेशन सर्टिफिकेट को लेकर अब कई तरह की समस्याएं (Problems) भी आने लगी हैं. कोरोना वैक्सीन लगवाने के बाद कुछ लोग इसलिए परेशान हैं कि उनके वैक्सीनेशन सर्टिफिकेट में…

[krazyshoppy]

कोविड का कहर जारी, ओमिक्रोन सबवेरिएंट अमेरिका में नए कोरोना संक्रमण का 35 प्रतिशत हिस्सा बना

कोविड का कहर ���ारी, ओमिक्रोन सबवेरिएंट अमेरिका में नए कोरोना संक्रमण का 35 प्रतिशत हिस्सा बना

दुनिया में कोरोना का कहर अभी भी बना हुआ है. हर रोज कोरोना के नए मामले सामने आ रहे हैं. इस बीच यूएस सेंटर फॉर डिजीज कंट्रोल एंड प्रिवेंशन (सीडीसी) द्वारा मंगलवार को अपडेट किए गए आंकड़ों के अनुसार, ओमिक्रोन वेरिएंट की बीए.2 उप-लाइनेज अब अमेरिका में नए कोविड-19 संक्रमणों का लगभग 35 प्रतिशत है. समाचार एजेंसी सिन्हुआ की रिपोर्ट के अनुसार, यह डेटा एक सप्ताह पहले के 22.3 प्रतिशत और दो सप्ताह पहले के…

[sareideas]

भारत में ओमिक्रॉन मामले 1,000 के पार, 450 केस के साथ महाराष्ट्र सबसे ऊपर - Sareideas

भारत में ओमिक्रॉन मामले 1,000 के पार, 450 केस के साथ महाराष्ट्र सबसे ऊपर – Sareideas

डिजिटल डेस्क,  नई दिल्ली। देश भर में पिछले 24 घंटों में अत्यधिक संक्रमणीय ओमिक्रॉन के 309 नए मामले सामने आए हैं। इसके साथ ही, भारत में ओमिक्रॉन मामलों की संख्या शुक्रवार को बढ़कर 1,270 हो गई। इनमें से 374 मरीजों को छुट्टी दे दी गई है। अब तक जिन 23 राज्यों और केंद्र शासित प्रदेशों ने ओमिक्रॉन संक्रमण की सूचना दी है, उनमें से महाराष्ट्र इस प्रकार के 450 मामलों के साथ सूची में सबसे ऊपर है। उनमें से…